Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits

Ultrasensitive methods for rare allele detection are critical to leverage the full potential offered by liquid biopsies. Here, we describe a novel molecular barcoding method for the precise detection and quantification of circulating tumor DNA (ctDNA). The major benefits of our design include straightforward and cost-effective production of barcoded adapters to tag individual DNA molecules before PCR and sequencing, and better control over cross-contamination between experiments. We validated our approach in a cohort of 24 patients with a broad spectrum of cancer diagnoses by targeting and quantifying single-nucleotide variants (SNVs), indels and genomic rearrangements in plasma samples. By using personalized panels targeting a priori known mutations, we demonstrate comprehensive error-suppression capabilities for SNVs and detection thresholds for ctDNA below 0.1%. We also show that our semi-degenerate barcoded adapters hold promise for noninvasive genotyping in the absence of tumor biopsies and monitoring of minimal residual disease in longitudinal plasma samples. The benefits demonstrated here include broad applicability, flexibility, affordability and reproducibility in the research and clinical settings.

[1]  Lawrence D True,et al.  Sequencing small genomic targets with high efficiency and extreme accuracy , 2015, Nature Methods.

[2]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[3]  Nitzan Rosenfeld,et al.  Circulating tumor-derived DNA is shorter than somatic DNA in plasma , 2015, Proceedings of the National Academy of Sciences.

[4]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[5]  Anton Nekrutenko,et al.  Streamlined analysis of duplex sequencing data with Du Novo , 2016, Genome Biology.

[6]  Takuma Iwai,et al.  Utility of KRAS mutation detection using circulating cell‐free DNA from patients with colorectal cancer , 2016, Cancer science.

[7]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[8]  Ryan D. Morin,et al.  Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies , 2016, Molecular Cancer Research.

[9]  M. Tewari,et al.  Mutant DNA quantification by digital PCR can be confounded by heating during DNA fragmentation. , 2016, BioTechniques.

[10]  Jue Ruan,et al.  Ultra-precise detection of mutations by droplet-based amplification of circularized DNA , 2016, BMC genomics.

[11]  I. Cree Liquid biopsy for cancer patients: Principles and practice , 2015 .

[12]  Suzanne E Dahlberg,et al.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.

[13]  R. Rosell,et al.  Real-time liquid biopsies become a reality in cancer treatment. , 2015, Annals of translational medicine.

[14]  Brendan F. Kohrn,et al.  Detecting ultralow-frequency mutations by Duplex Sequencing , 2014, Nature Protocols.

[15]  Xianshu Gao,et al.  "Liquid biopsy"-ctDNA detection with great potential and challenges. , 2015, Annals of translational medicine.

[16]  V. Wong,et al.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients , 2015, Proceedings of the National Academy of Sciences.

[17]  M. Tiseo,et al.  Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. , 2015, Translational lung cancer research.

[18]  Giuseppe Curigliano,et al.  Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. , 2016, Pharmacology & therapeutics.

[19]  A. Quintás-Cardama,et al.  BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase , 2015, Leukemia.

[20]  R. Zárate,et al.  Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors , 2014 .

[21]  Salvatore Piscuoglio,et al.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma , 2015, Nature Communications.

[22]  J. Ludden,et al.  Principles and Practice , 1998, Community-based Learning and Social Movements.

[23]  Johan Skog,et al.  Liquid biopsy for cancer screening, patient stratification and monitoring , 2018 .

[24]  W. Liang,et al.  Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report , 2016, BMC Cancer.

[25]  Masahiko Ando,et al.  Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR , 2015, Clinical Cancer Research.

[26]  R. Morin,et al.  Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. , 2016, Clinical chemistry.

[27]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[28]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[29]  A. Bardelli,et al.  Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance , 2014, Genome Biology.

[30]  A. Jakobsen,et al.  Screening for circulating RAS/RAF mutations by multiplex digital PCR. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[31]  Karla Perez-Toralla,et al.  Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations , 2016, PloS one.

[32]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[33]  Nolan G. Ericson,et al.  Targeted single molecule mutation detection with massively parallel sequencing , 2015, Nucleic acids research.

[34]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[35]  Ryan D. Morin,et al.  Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. , 2016, Blood.

[36]  Ryan D. Morin,et al.  Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas , 2015, Clinical Cancer Research.

[37]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[38]  Cheng Qian,et al.  Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer , 2016, Oncotarget.

[39]  V. Marx Cancer: hunting rare somatic mutations , 2016, Nature Methods.

[40]  T. Godfrey,et al.  Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR. , 2016, The Journal of molecular diagnostics : JMD.

[41]  P. Laurent-Puig,et al.  Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.

[42]  Jesse J. Salk,et al.  Detection of ultra-rare mutations by next-generation sequencing , 2012, Proceedings of the National Academy of Sciences.